Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05544019 · ClinicalTrials.gov registry record · Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
A Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Schrödinger.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT05544019 is a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Schrödinger. The registered enrollment target is 98 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05544019, a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Schrödinger.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Conditions Studied
Interventions
- DRUG SGR-1505
Study Locations (20)
Other
- AP-HP Hôpital Henri-Mondor - Créteil
- Institut Gustave Roussy - Villejuif
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile - Alessandria
- ASST Grande Ospedale Metropolitano Niguarda - Milan
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Weill Cornell - New York
- Montefiore Medical Center - The Bronx
Ohio
- Gabrail Cancer & Research Center - Canton
- The Ohio State University - The James Cancer Hospital - Columbus
Arizona
- Banner Health - MD Anderson Cancer Center - Gilbert
Delaware
- Christiana Care Hospital - Helen F Graham Cancer Center - Newark
Florida
- Napa Research - Pompano Beach
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Regional Cancer Care Associates - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05544019
The ClinicalTrials.gov registry entry for NCT05544019 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (35% lower). The listed sponsor is Schrödinger, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGR-1505 is the first listed.
NCT05544019 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05544019 about?
NCT05544019 is a clinical study titled "Study of SGR-1505 in Mature B-Cell Neoplasms". The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
What is the current status of trial NCT05544019?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-04-10. Estimated completion is 2027-11.
What conditions does trial NCT05544019 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, DLBCL.
What interventions are being tested in trial NCT05544019?
The interventions under investigation include: SGR-1505 (DRUG).
Who is sponsoring clinical trial NCT05544019?
This trial is sponsored by Schrödinger, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05544019 being conducted?
This trial has 20 study locations across Arizona, Delaware, Florida, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.